Literature DB >> 12360044

Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis.

Elizabeth Montgomery1, Michael S Torbenson, Manju Kaushal, Cyril Fisher, Susan C Abraham.   

Abstract

Although separating gastrointestinal stromal tumor (GIST) from mesenteric fibromatosis and sclerosing mesenteritis is clinically important, this distinction sometimes poses problems for practicing pathologists. In the STI571 (Gleevec, Imatinib) era, the problem may be further compounded when protocol-driven staining for CD117 (c-kit) is performed on spindle cell proliferations presenting in the bowel wall and mesentery using an antibody known to react with the majority of mesenteric fibromatoses when other antibodies are more specific. Because most mesenteric fibromatoses have mutations in the pathway and hence have abnormal nuclear accumulation of beta-catenin protein, we studied beta-catenin expression among a panel of other immunohistochemical stains to distinguish mesenteric fibromatosis, GIST, and sclerosing mesenteritis. Examples of gastrointestinal stromal tumors (GIST, 11), sclerosing mesenteritis (5), and mesenteric fibromatosis (10) were retrieved from the archives of our institutions. Cases were studied with an immunohistochemical panel consisting of CD117, beta-catenin, CD34, smooth muscle actin, desmin, keratin, and S-100 protein. Cases were scored as "negative," "focally positive," or "diffusely positive." In evaluating beta-catenin, nuclear accumulation was required. GIST all had CD117 (11 of 11, diffuse) and CD34 (11 of 11, diffuse) with variable actin (5 of 11, focal) and negative desmin, keratin, S-100 protein. All GIST lacked beta-catenin (0 of 11). Mesenteric fibromatosis had CD117 (6 of 10, 3 focal, 3 diffuse), typically expressed more weakly than in GIST, actin (5 of 9, focal), and desmin (3 of 8, focal) in keeping with myofibroblastic differentiation but lacked CD34, S-100, and keratin. CD117 staining was not eliminated by use of a non-avidin-biotin technique. Nuclear beta-catenin was detected in 9 of 10 fibromatoses, including one case associated with familial adenomatous polyposis. Two of five sclerosing mesenteritis cases focally expressed CD117. None of the sclerosing mesenteritis cases had nuclear beta-catenin. Sclerosing mesenteritis cases were otherwise fibroblastic and myofibroblastic with focal actin in 5 of 5 and negative desmin, keratin, and S-100 protein but one had CD34 (1 of 5, focal). With increasing protocol-driven interest in evaluating bowel wall and mesenteric spindle cell lesions using CD117 (c-kit) antibodies, it is important for practicing pathologists to be aware that lesions other than GISTs are likely to express this antigen using certain antibodies. beta-Catenin staining identifies lesions that are, instead, mesenteric fibromatoses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360044     DOI: 10.1097/00000478-200210000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  41 in total

1.  Mesenteric fibromatosis of the transverse colon with the reconstruction of the superior mesenteric arteries: report of a case.

Authors:  Makoto Seki; Rintaro Koga; Akio Saiura; Ken Nakagawa; Kazuyoshi Kawabata; Hiroaki Kanda; Mutsuo Machinami; Masaru Nakagawa
Journal:  Surg Today       Date:  2012-05-18       Impact factor: 2.549

2.  Computed tomographic presentation of mesenteric fibromatosis.

Authors:  Ching-Hsiang Yang; Shyr-Ming Sheen-Chen; Chien-Chang Lu; Sheung-Fat Ko; Hock-Liew Eng
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 3.  Occasional finding of mesenteric lipodystrophy during laparoscopy: a difficult diagnosis.

Authors:  Nereo Vettoretto; Domenico-Roberto Diana; Roberto Poiatti; Armando Matteucci; Caterina Chioda; Maurizio Giovanetti
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

4.  Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.

Authors:  Shan Zeng; Adrian M Seifert; Jennifer Q Zhang; Michael J Cavnar; Teresa S Kim; Vinod P Balachandran; Juan A Santamaria-Barria; Noah A Cohen; Michael J Beckman; Benjamin D Medina; Ferdinand Rossi; Megan H Crawley; Jennifer K Loo; Joanna H Maltbaek; Peter Besmer; Cristina R Antonescu; Ronald P DeMatteo
Journal:  Mol Cancer Ther       Date:  2017-06-13       Impact factor: 6.261

5.  Orthopaedic case of the month: Painless right knee mass in 32-year-old man.

Authors:  Michael K Merz; Mansooreh Eghtesadghalati; Michael E Bresler; Yasser R Farid
Journal:  Clin Orthop Relat Res       Date:  2012-09-12       Impact factor: 4.176

6.  Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors.

Authors:  Nicholas A Mignemi; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Hernan Correa; Cheryl M Coffin; Jennifer O Black; Yajun Yi; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Jonathan G Schoenecker; Justin M M Cates
Journal:  Cancer Sci       Date:  2012-11-15       Impact factor: 6.716

7.  A practical and comprehensive immunohistochemical approach to the diagnosis of superficial soft tissue tumors.

Authors:  Wael Al-Daraji; Ehab Husain; Bettena G Zelger; Bernhard Zelger
Journal:  Int J Clin Exp Pathol       Date:  2008-06-10

8.  Benign mesenteric lipodystrophy presenting as low abdominal pain: a case report.

Authors:  Jonathan Richard Rees; Phillip Burgess
Journal:  J Med Case Rep       Date:  2010-04-27

9.  Simultaneous Colonic Obstruction and Hydroureteronephrosis due to Mesenteric Fibromatosis.

Authors:  Sung Hoon Jung; Chang Nyol Paik; Ji Han Jung; Kang-Moon Lee; Woo Chul Chung; Jin-Mo Yang
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

10.  Ultrastructural studies of gastrointestinal stromal tumors.

Authors:  Sung-Hye Park; Min-Kyung Kim; Hanseong Kim; Byung Joo Song; Je G Chi
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.